Rheumatology Advance Access originally published online on March 1, 2005
Rheumatology 2005 44(6):777-780; doi:10.1093/rheumatology/keh592
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis
Department of Pediatrics-Rheumatology Unit and 1 Department of Pediatrics, University of Florence, Italy.
Correspondence to: G. Simonini, Department of Pediatrics-Rheumatology Unit, Via Pico della Mirandola 24, 50132 Firenze, Italy. E-mail: gabriele.simonini{at}unifi.it
Objective. To evaluate bone mineral status over 1 yr of etanercept treatment in juvenile idiopathic arthritis (JIA).
Methods. Twenty children (13 female, 7 male) aged 5.2–11.4 yr, with active polyarticular JIA were prospectively enrolled to receive etanercept (0.4 mg/kg, twice weekly). Responders were defined according to the American College of Rheumatology Pediatric 50 definition of improvement. Broadband ultrasound attenuation (BUA) by bone was determined at the left calcaneus to assess bone status at baseline and at 1-yr follow-up.
Results. After 12 months of treatment, 15 (75%) patients were considered as responders. At baseline, responders and non-responders did not differ with regard to age, disease duration, core-set variables or BUA and Z-score values (patient's value – age specific normal value/normal group's S.D.). At 6-month and 1-yr follow-up in the whole group, BUA and Z-score values were not significantly different compared with baseline. At 1-yr follow-up, but not at 6 months, all 15 responders, differently from non-responders, showed a significant increase in both BUA and Z-score values: BUA at 1 yr 55.2 ± 3.3 vs baseline 43.5 ± 3.2 dB/MHz, P<0.001; Z score at 1 yr –0.3 ± 0.2 vs baseline 1.5 ± 0.4, P<0.002.
Conclusion. For the first time in childhood rheumatic disease this pilot prospective study, although in a small group, shows evidence that 1 yr of etanercept therapy by controlling the underlying disease activity induces a sustained benefit on JIA bone loss. Prospective studies in larger patient samples are needed to confirm these data.
KEY WORDS: Juvenile idiopathic arthritis, Etanercept, Bone mineral status
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Lilleby Review: Bone status in juvenile systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 580 - 586. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Galluzzi, S. Stagi, R. Salti, S. Toni, E. Piscitelli, G. Simonini, F. Falcini, and F. Chiarelli Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status Eur. J. Endocrinol., December 1, 2005; 153(6): 879 - 885. [Abstract] [Full Text] [PDF]
|
|